Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05952453
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
  • olaparibp, embro — DRUG
    maintenance chemotherapy : olaparib, pembro

Study Details

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

Key Dates

Start date
Feb 17, 2025
Status verified
Mar 2026
Primary completion
Oct 30, 2028
Completion
Dec 30, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Carbo/taxol/pembro followed by maintenance of olaparib/pembro post-surgery
    neoadjuvant carbo/taxol/pembro followed by maintenance olaparib/pembro post- surgery

Primary Outcome Measure

Progression free survival [ Time Frame: 36 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
O'Neal Comprehensive Cancer Center at UABBirminghamAlabama35294
Margaret A Thomas, MPH
[email protected]
Rebecca Arend, MD, MSPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
O'Neal Comprehensive Cancer Center at UAB· Birmingham, AL

Related Studies